| Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma HM Lokhorst, T Plesner, JP Laubach, H Nahi, P Gimsing, M Hansson, ... New England Journal of Medicine 373 (13), 1207-1219, 2015 | 1276 | 2015 |
| Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1211 | 2016 |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and … M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ... The Lancet Haematology 7 (6), e456-e468, 2020 | 320 | 2020 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study S Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Blood 128 (22), 4414-4414, 2016 | 319 | 2016 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 317 | 2017 |
| Biosynthesis, processing, and sorting of human myeloperoxidase M Hansson, I Olsson, WM Nauseef Archives of biochemistry and biophysics 445 (2), 214-224, 2006 | 298 | 2006 |
| Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. M Hansson, A Asea, U Ersson, S Hermodsson, K Hellstrand The Journal of Immunology 156 (1), 42-47, 1996 | 269 | 1996 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 242 | 2019 |
| Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine UH Mellqvist, M Hansson, M Brune, C Dahlgren, S Hermodsson, ... Blood, The Journal of the American Society of Hematology 96 (5), 1961-1968, 2000 | 208 | 2000 |
| Genome-wide association study identifies multiple susceptibility loci for multiple myeloma JS Mitchell, N Li, N Weinhold, A Försti, M Ali, M Van Duin, G Thorleifsson, ... Nature communications 7 (1), 1-9, 2016 | 183 | 2016 |
| Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma MA Dimopoulos, A Palumbo, P Corradini, M Cavo, M Delforge, ... Blood, The Journal of the American Society of Hematology 128 (4), 497-503, 2016 | 169 | 2016 |
| International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) MV Mateos, S Kumar, MA Dimopoulos, V González-Calle, E Kastritis, ... Blood Cancer Journal 10 (10), 1-11, 2020 | 166 | 2020 |
| Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma MA Dimopoulos, X Leleu, A Palumbo, P Moreau, M Delforge, M Cavo, ... Leukemia 28 (8), 1573-1585, 2014 | 154 | 2014 |
| Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo A Roghanian, I Teige, L Mårtensson, KL Cox, M Kovacek, A Ljungars, ... Cancer Cell 27 (4), 473-488, 2015 | 147 | 2015 |
| Robust isolation of malignant plasma cells in multiple myeloma I Frigyesi, J Adolfsson, M Ali, M Kronborg Christophersen, E Johnsson, ... Blood, The Journal of the American Society of Hematology 123 (9), 1336-1340, 2014 | 125 | 2014 |
| Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma S Zweegman, B van der Holt, UH Mellqvist, M Salomo, GMJ Bos, ... Blood, The Journal of the American Society of Hematology 127 (9), 1109-1116, 2016 | 110 | 2016 |
| Histamine protects T cells and natural killer cells against oxidative stress M Hansson, S Hermodsson, M Brune, UH Mellqvist, P Naredi, Å Betten, ... Journal of interferon & cytokine research 19 (10), 1135-1144, 1999 | 110 | 1999 |
| Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma M Went, A Sud, A Försti, BM Halvarsson, N Weinhold, S Kimber, ... Nature communications 9 (1), 1-10, 2018 | 109 | 2018 |
| Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for … P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... Blood 126 (23), 727-727, 2015 | 98 | 2015 |
| Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis J Aurelius, FB Thorén, AA Akhiani, M Brune, L Palmqvist, M Hansson, ... Blood 119 (24), 5832-5837, 2012 | 98 | 2012 |
